Alexandra Ward, MA, is vice president of content at MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys cooking, biking, and her dog Bo. Follow her on Twitter at @allie_ward or email her at [email protected]
Mesenchymal Stem Cell Therapy an Option for Patients With Type 2 Diabetes Complications
May 17th 2022Investigators in Ukraine share data on the safety and efficacy of autologous mesenchymal stem cell administration for type 2 diabetes complications under the hypothesis that success is dependent on the administration route and quality of the autologous MSC population.
Early Momentum for a Genomic Approach to Sickle Cell Disease Therapy
May 17th 2022In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).
CAR T-Cell Therapy Effective Without Toxicity Risk in Patients With Primary/Secondary CNS Lymphoma
April 25th 2022In this late-breaking poster presented at the Tandem Meetings, investigators recommend that patients with primary or secondary central nervous system lymphoma be included in future clinical trials for CAR T-cell therapy.
FBX-101 and the RESKUE Trial: Exploring AAV-Based Gene Therapies for Krabbe Disease
April 15th 2022Erandi De Silva, PhD, co-founder and senior vice president of product development at Forge Biologics, discusses the dual approach of her company in manufacturing and also developing adeno-associated viral (AAV) -based gene therapies, including FBX-101 for Krabbe disease.